Marshall Wace North America L.P. lifted its position in shares of Zoetis Inc (NYSE:ZTS) by 32.6% during the third quarter, HoldingsChannel reports. The firm owned 4,202,241 shares of the company’s stock after acquiring an additional 1,034,161 shares during the quarter. Zoetis makes up about 2.6% of Marshall Wace North America L.P.’s portfolio, making the stock its 2nd largest holding. Marshall Wace North America L.P.’s holdings in Zoetis were worth $384,757,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently bought and sold shares of ZTS. Marshall Wace LLP increased its position in Zoetis by 76.4% in the 3rd quarter. Marshall Wace LLP now owns 3,216,573 shares of the company’s stock valued at $294,509,000 after acquiring an additional 1,393,397 shares during the period. MARSHALL WACE ASIA Ltd acquired a new position in Zoetis in the 3rd quarter valued at about $9,773,000. Great Lakes Advisors LLC increased its position in Zoetis by 201.5% in the 3rd quarter. Great Lakes Advisors LLC now owns 48,635 shares of the company’s stock valued at $4,453,000 after acquiring an additional 32,502 shares during the period. Carnegie Capital Asset Management LLC increased its position in Zoetis by 34.9% in the 3rd quarter. Carnegie Capital Asset Management LLC now owns 226,671 shares of the company’s stock valued at $20,909,000 after acquiring an additional 58,663 shares during the period. Finally, Belpointe Asset Management LLC acquired a new position in Zoetis in the 3rd quarter valued at about $328,000. Institutional investors and hedge funds own 89.94% of the company’s stock.
In other Zoetis news, insider Kristin C. Peck sold 11,500 shares of Zoetis stock in a transaction that occurred on Monday, November 12th. The stock was sold at an average price of $94.78, for a total value of $1,089,970.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Roxanne Lagano sold 2,000 shares of Zoetis stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $92.03, for a total value of $184,060.00. The disclosure for this sale can be found here. Insiders sold a total of 169,511 shares of company stock worth $16,081,299 in the last ninety days. 0.35% of the stock is owned by corporate insiders.
Several brokerages recently issued reports on ZTS. Argus set a $105.00 price target on Zoetis and gave the company a “buy” rating in a research report on Tuesday, November 13th. BMO Capital Markets boosted their price target on Zoetis to $93.00 and gave the company a “neutral” rating in a research report on Monday, November 12th. They noted that the move was a valuation call. JPMorgan Chase & Co. boosted their price target on Zoetis from $100.00 to $101.00 and gave the company an “overweight” rating in a research report on Friday, November 2nd. Morgan Stanley set a $100.00 price target on Zoetis and gave the company a “hold” rating in a research report on Friday, November 2nd. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $105.00 price target (up previously from $98.00) on shares of Zoetis in a research report on Wednesday, October 17th. Six analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $94.00.
ZTS traded down $0.16 during trading on Thursday, reaching $90.41. The company’s stock had a trading volume of 2,992,718 shares, compared to its average volume of 2,520,083. Zoetis Inc has a 52-week low of $70.20 and a 52-week high of $96.57. The firm has a market capitalization of $43.51 billion, a PE ratio of 37.67, a P/E/G ratio of 1.79 and a beta of 0.99. The company has a current ratio of 4.06, a quick ratio of 2.63 and a debt-to-equity ratio of 3.04.
Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, November 1st. The company reported $0.83 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.77 by $0.06. Zoetis had a return on equity of 75.51% and a net margin of 20.35%. The company had revenue of $1.48 billion for the quarter, compared to analyst estimates of $1.46 billion. During the same quarter in the previous year, the company earned $0.65 EPS. The firm’s revenue for the quarter was up 9.9% compared to the same quarter last year. On average, sell-side analysts predict that Zoetis Inc will post 3.11 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 3rd. Shareholders of record on Tuesday, November 20th were issued a $0.126 dividend. This represents a $0.50 dividend on an annualized basis and a yield of 0.56%. The ex-dividend date of this dividend was Monday, November 19th. Zoetis’s dividend payout ratio is presently 20.83%.
ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/12/06/marshall-wace-north-america-l-p-purchases-1034161-shares-of-zoetis-inc-zts.html.
Zoetis, Inc discovers, develops and manufactures a portfolio of animal health medicines and vaccines. Its products are complemented by diagnostic products, genetic tests, bio devices and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal. The firm provides its services though five categories namely, anti-invectives, vaccines, parasitic ides, medicated feed additives, and other pharmaceuticals.
Recommended Story: How Investors Use a Balance Sheet
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.